High Quality Anti-Tumor Raw Powder Topotecan Hydrochloride CAS 119413-54-6

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP
• Suitable for: Adult
• State: Solid
• Purity: >99%
• Model NO.: TGY022019061916
• Product Name: Topotecan Hydrochloride
• Specificcation: 99%
• Grade: Medicine Grade
• Storage: Cool Dry Place
• Shipping Time: Within 3-7 Working Days
• CAS: 119413-54-6
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• HS Code: 300440906
• Production Capacity: 1500kg/Month

Product Description

Product Name	Topotecan hydrochloride
CAS No.	119413-54-6
Molecular Formula	C23H24ClN3O5
Molecular Weight	457.91
EINECS No.	1308068-626-2
Melting point	213-218°C
Boiling point	782.9ºC at 760mmHg
Flash point	427.3ºC
Steam pressure	8.13E-26mmHg at 25°C
PSA	104.89000
LogP	2.64880
Refractive index	1.733
Appearance	White Powder
Purity	99%
Quality Standard	Enterprise standard
Storage Conditions	Refrigerator
Packing	1kg/foil bag;25kg/drum
Shipment	EMS;DHL;FedEx;TNT;UPS
Delivery Time	4-7 Working Days
Payment terms	T/T;Western Union;Money Gram;Bitcoin
Usage	The best drugs for the treatment of ovarian cancer at present; Treatment of breast cancer, rectal cancer, colon cancer, acute and chronic white blood cell disease; used as anti-tumor drugs

 
<sub>Topotecan hydrochloride is a water-soluble derivative of camptothecin, which is the form of hydrochloride of topotecan. It is successfully developed by the SmithKline Beecham US company, and approved by the FDA in the United States in 1996. Its trade name is Hycamtin. It is applied in the treatment of ovarian cancer (OVC) as the second-line therapy. 

In 1999 the US Food and Drug Administration (FDA) has approved topotecan hydrochloride as small cell lung cancer (SCLC) therapeutic drug. It has been available in the UK, Germany, France and other dozens of countries and regions. The 3 clinical trials are ongoing for this medicine which is used to treat non-small cell lung cancer, cervical cancer, myelodysplastic syndrome. 

Topotecan hydrochloride can enter the blood brain barrier. It has the same effect of oral and intravenous injection. The drug has low toxicity predictable bone marrow suppression, and other minor non-hematologic toxicity. Currently there are manufacturers, for clinical treatment of small cell lung cancer, ovarian cancer and other tumors.

Topotecan hydrochloride inhibits the activity of topoisomerase I, which is required for DNA replication. After intravenous injection, the product is hydrolyzed in the blood, and excreted by urinary. This product has a rapid serum clearance rate, which is 62L/h. It is widely distributed in vivo, and Its half-lifetime is about 2~3h. Preclinical trials have shown that the product has anti-tumor activity on all kinds of types of tumor. In I clinical trial, to patients with ovarian cancer that is cisplatin tolerance, this product also has significant anti-tumor effect.</sub>